Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Rutkowski

Showing results (51-60 of 253) with videos related to

Pageof 26
Sort By:
Cancers|March 28, 2024
Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. <i>Cancers</i> 2022, <i>14</i>, 374Simon Bailey, Nicolas André, Lorenza Gandola, et al.
Journal of Cancer Survivorship : Research and Practice|July 24, 2021
Fear of progression in parents of childhood cancer survivors: prevalence and associated factorsMona L Peikert, Laura Inhestern, Konstantin A Krauth, et al.
Cancers|December 10, 2021
SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk MedulloblastomaMartin Mynarek, Till Milde, Laetitia Padovani, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|June 1, 2020
Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcomeStephanie T Jünger, Felipe Andreiuolo, Martin Mynarek, et al.
Journal of Neuro-Oncology|August 6, 2008
Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade gliomaJohannes E A Wolff, Christof Kramm, Rolf-Dieter Kortmann, et al.
Neuro-Oncology|January 29, 2014
MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system Marco Gessi, André O von Bueren, Andras Treszl, et al.
Acta Neuropathologica|February 1, 2007
Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survivalInna Lukashova-v Zangen, Susanne Kneitz, Camelia-Maria Monoranu, et al.
Pediatric Blood & Cancer|February 11, 2010
Medulloblastoma in young childrenStefan Rutkowski, Bruce Cohen, Jonathan Finlay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2011
Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patientsMarkus Priller, Julia Pöschl, Leticia Abrão, et al.
Psycho-Oncology|March 2, 2025
Beyond Treatment: Prevalence, Predictors, and Changes in Anxiety and Depression Among Parents of Childhood Cancer SurvivorsHannah Kurz, Verena Paul, Mona L Nasse, et al.
Pageof 26

Showing results (51-60 of 253) with videos related to

Sort By:
Pageof 26
Cancers|March 28, 2024
Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. <i>Cancers</i> 2022, <i>14</i>, 374Simon Bailey, Nicolas André, Lorenza Gandola, et al.
Journal of Cancer Survivorship : Research and Practice|July 24, 2021
Fear of progression in parents of childhood cancer survivors: prevalence and associated factorsMona L Peikert, Laura Inhestern, Konstantin A Krauth, et al.
Cancers|December 10, 2021
SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk MedulloblastomaMartin Mynarek, Till Milde, Laetitia Padovani, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|June 1, 2020
Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcomeStephanie T Jünger, Felipe Andreiuolo, Martin Mynarek, et al.
Journal of Neuro-Oncology|August 6, 2008
Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade gliomaJohannes E A Wolff, Christof Kramm, Rolf-Dieter Kortmann, et al.
Neuro-Oncology|January 29, 2014
MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system Marco Gessi, André O von Bueren, Andras Treszl, et al.
Acta Neuropathologica|February 1, 2007
Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survivalInna Lukashova-v Zangen, Susanne Kneitz, Camelia-Maria Monoranu, et al.
Pediatric Blood & Cancer|February 11, 2010
Medulloblastoma in young childrenStefan Rutkowski, Bruce Cohen, Jonathan Finlay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2011
Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patientsMarkus Priller, Julia Pöschl, Leticia Abrão, et al.
Psycho-Oncology|March 2, 2025
Beyond Treatment: Prevalence, Predictors, and Changes in Anxiety and Depression Among Parents of Childhood Cancer SurvivorsHannah Kurz, Verena Paul, Mona L Nasse, et al.
Pageof 26